Helmholtz Zentrum München

What Helmholtz Zentrum München does

Helmholtz Zentrum München (trading as Helmholtz Munich) is a German biomedical research institution founded in 1960 and headquartered in Neuherberg, near Munich. Legally organized as a non-profit limited liability company — Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) — it operates as part of the Helmholtz Association, Germany's national research infrastructure network funded by the federal and state governments. With a headcount of 1,001–5,000, the center conducts fundamental and translational research organized across seven major centers: the Helmholtz Diabetes Center, Environmental Health Center, Molecular Targets and Therapeutics Center, Stem Cell Center, Bioengineering Center, Computational Health Center, and the Helmholtz Pioneer Campus. The Environmental Health Center alone spans 12+ institutes and the Diabetes Center 16+ research units.

The organization's core technical capabilities include computational protein design, AI/machine learning for biomedical data and imaging, cryo-electron microscopy, bioengineering, stem cell and metabolic research. Notable outputs include novel near-infrared and short-wave infrared fluorescent proteins engineered via computational protein design (enabling deeper tissue penetration than traditional GFP), an experimental "five-in-one" multi-targeted metabolic compound combining GLP-1 and GIP receptor agonists with lanifibranor, and AI-for-Health applications spanning disease detection, personalized medicine, and whole-body damage mapping in obesity. It also runs long-running clinical research programs such as the Fr1da study for early Type-1 Diabetes detection in children.

As a publicly funded research entity, Helmholtz Munich does not operate commercial products or services with standard pricing; it is funded primarily through government research grants via the Helmholtz Association. Its "go-to-market" is knowledge and technology transfer: a dedicated Technology Transfer Office licenses patents and innovations to pharmaceutical and biotech partners, and collaborative research agreements are run through its cooperation network (Kooperationsnetzwerk). Its principal beneficiaries are academic and research institutions worldwide, and healthcare providers and clinical research institutions (e.g., diabetes screening programs).

Name

Helmholtz Zentrum München

Legal name

Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

Website

https://helmholtz-muenchen.de

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Helmholtz Munich (Helmholtz Zentrum München) is a German government-funded, non-profit biomedical research center in Neuherberg conducting research across diabetes, environmental health, computational health, stem cells, bioengineering and molecular therapeutics, serving academic, clinical and industry partners worldwide.

Ownership category

akta.pro rank

Product category

Biomedical Research Institution

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

Keywords

• Biomedical research
• Diabetes research
• Computational health
• Bioengineering imaging
• Stem cell research

Headquarters

HQ city

Neuherberg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels2 records

Marketing channels4 records

Core offering

Helmholtz Munich is a German public research center for health and environment that conducts fundamental and translational biomedical research across diabetes, environmental health, computational health, stem cells, bioengineering, and molecular therapeutics. Its outputs are scientific discoveries, technologies, patents, and trained scientific talent, transferred to industry via licensing and collaborations.

Product overview

Helmholtz Zentrum München is a German research center (Helmholtz Munich) focused on developing breakthrough solutions for healthier societies. The institution conducts research across seven main areas: Diabetes & Adipositas (Helmholtz Diabetes Center), Computational Health, Stem Cells, Environmental Health, Bioengineering, Molecular Targets and Therapies, and the Helmholtz Pioneer Campus. The research portfolio includes early disease detection programs (such as the Fr1da study for Type 1 Diabetes screening in children), metabolic disease research, environmental health studies, AI applications in health, bioengineering innovations, and molecular therapeutics development. Helmholtz Munich also operates Core Facilities providing specialized scientific services and offers scientific talent development programs including graduate education and postdoctoral training. No commercial products or services are offered; all activities are focused on scientific research and knowledge transfer.

Differentiator

Problem solved

Functional benefit

Products and services

• Helmholtz Diabetes Center Research center focused on diabetes and obesity, including metabolic disease research and early disease detection programs such as the Fr1da study for Type 1 Diabetes screening in children.
• Computational Health Center Research center applying AI and machine learning to health, including disease detection, personalized medicine, and computational biology for biomedical data analysis.
• Bioengineering Center Research center developing biomedical imaging technologies and bioengineering innovations to address critical medical needs.
• Stem Cell Center Research center investigating stem cell biology and neurogenesis mechanisms for regenerative medicine applications.
• Environmental Health Center Research center studying environmental impacts on disease, including allergy, asthma prevention, microbiome, lung research, epidemiology, and global health.
• Molecular Targets and Therapeutics Center Research center using structural biology and medicinal chemistry to elucidate molecular mechanisms and enable structure-based drug development for cancer and viral infections.
• Core Facilities Specialized scientific services including bioinformatics and statistics, flow cytometry, genomics, induced pluripotent stem cells, laboratory animal services, metabolomics and proteomics, monoclonal antibodies, and pathology/tissue analytics.
• Technology Transfer Structured technology transfer process for licensing patents and innovations to industry partners including pharmaceutical and biotech companies.
• Scientific Talent and Career Development Programs Graduate education (Helmholtz Munich Graduate School HELENA), postdoctoral training, and scientific training programs for early-career researchers.
• Near-infrared and short-wave infrared fluorescent proteins Novel fluorescent proteins developed using computational protein design that emit light in near-infrared and short-wave infrared spectra, enabling deeper tissue penetration and reduced autofluorescence for biomedical imaging and cancer detection during surgery.
• Five-in-one multi-targeted metabolic compound Experimental compound combining GLP-1 and GIP receptor agonists with lanifibranor to target five metabolic pathways simultaneously for diabetes and weight loss treatment.

Quantifiable outcome

• Early-stage Type-1 Diabetes detection demonstrated as broadly implementable through the Fr1da study over 10 years of research
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core.

• German Center for Diabetes ResearchcoreStrategic or Co-development Partner · 1 January 2025Partnership on research presenting groundbreaking 'five-in-one' experimental compound combining GLP-1, GIP receptor agonists with lanifibranor for multi-targeted metabolic therapy at EASD 2025 Annual Meeting
• National Center for Tumor Diseases DresdencoreStrategic or Co-development PartnerInternational research collaboration led by Professor Oliver Bruns to develop novel near-infrared fluorescent proteins using computational protein design, with applications for cancer detection during surgery and disease monitoring
• University of WashingtoncoreStrategic or Co-development PartnerInternational research collaboration on the development of novel fluorescent proteins using computational protein design for deeper tissue imaging applications
• Howard Hughes Medical InstitutecoreStrategic or Co-development PartnerInternational research collaboration on novel fluorescent proteins using computational protein design for biomedical imaging applications
• German Cancer Research Center (DKFZ)coreStrategic or Co-development PartnerCollaboration on international research team developing novel near-infrared fluorescent proteins with applications in cancer detection and disease monitoring
• Accure TherapeuticscoreStrategic or Co-development PartnerAccure Therapeutics has filed a patent for new oligopeptide derivatives as MMP-2 and MMP-9 inhibitors targeting viral infections and cancer, expanding the company's therapeutic compound portfolio through the partnership with Helmholtz Munich research
• Ludwig-Maximilians-Universität München (LMU)coreStrategic or Co-development PartnerCollaborating research institution on AI health initiatives including the development of AI atlas for mapping whole-body damage caused by obesity

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• German Cancer Research Center (DKFZ): Fellow Helmholtz Association center in Heidelberg focused on cancer biology and translational oncology. Comparable as a large-scale government-funded biomedical research institute with overlapping faculty, technology transfer, and partnership networks.
• Max Delbrück Center for Molecular Medicine (MDC): Berlin-based Helmholtz center focused on molecular medicine, cardiovascular and metabolic disease, and computational biology. Directly comparable in size, funding structure, AI-for-health focus, and translational pipeline.
• Max Planck Institute for Biochemistry: Max Planck Society institute in Martinsried near Munich conducting basic research in structural biology, proteomics, and molecular medicine. Closely co-located with Helmholtz Munich and overlapping in cryo-EM, structural biology, and molecular targets.
• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization in life sciences with multiple sites across Europe. Comparable scale, multi-disciplinary structure, and emphasis on structural biology, imaging, and computational biology.
• INSERM: French national institute for health and medical research — the principal European counterpart to the Helmholtz Association's health centers. Comparable non-profit, government-funded structure across multiple research domains including diabetes, oncology, and environmental health.
• Fraunhofer Society: German applied-research counterpart to Helmholtz, structured as a network of institutes conducting contract R&D for industry. Relevant peer for tech-transfer model, biomedical engineering units, and Helmholtz-Pioneer-Campus-style innovation programs.
• Pasteur Institute: French non-profit research institute focused on infectious disease, immunology, and developmental biology. Comparable non-profit, multi-center structure, with overlapping themes in virology, immunology, and public health.

Broad incumbents

• Broad Institute: Large US-based biomedical and genomic research institute affiliated with MIT and Harvard. Comparable in scale and ambition at the AI-for-biology, genomics, and chemical biology frontier; broader funding sources and deeper commercialization pipeline.
• Wellcome Sanger Institute: UK-based, Wellcome Trust–funded genomics and translational research institute. Comparable in scale, AI-genomics capability, and population-scale screening programs (e.g., equivalent to Fr1da).
• Karolinska Institutet: Swedish medical university with large translational research portfolio spanning metabolic disease, regenerative medicine, and epidemiology. Comparable translational focus and Scandinavian/Nordic public-health research model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/storgy
• YouTubeyoutube.com/user/helmholtzmuenchen
• LinkedInlinkedin.com/company/helmholtz-muenchen
• Instagraminstagram.com/helmholtz_munich

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helmholtz Zentrum München